Clinical Trial Update: Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating in-home versus in-clinic subcutaneous nivolumab administration under the CC Beyond Walls program; the study is currently recruiting. It…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Cutaneous Melanoma
• Esophageal Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Opdivo (nivolumab) (nivolumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Status: RECRUITING